Michela Emma Burlone

Curriculum vitae

PERSONAL DATA

Place and date of birth: Novara, 18 July 1978

Address: via Varallino, 72 28066-Galliate

Cell: +39-3396169501

Work address: via Solaroli, 17 28100-Novara

Tel: +39-0321-3733846

BIO AND EDUCATION

1997 High school degree c/o Liceo Classico Statale "Carlo Alberto" of Novara, 60/60.

2003- 2012 Clinical fellow, Internal Medicine Division, cellular and molecular biology Laboratory, University of East Piedmont "Amedeo Avogadro", Italy (Tutor: Prof. Mario Pirisi).

07/2004 Degree in Medicine (103/110), University of East Piedmont "Amedeo Avogadro", Italy.

02/2005 Qualifying exam for professional activity.

8/2004-11/2005 Intern at Internal Medicine Division, University of Eastern Piedmont "Amedeo Avogadro", Italy.

1/11/2007- 31/07/2008 Internal fellowship in the Hepacivirus Unit, Insitute Pasteur, Paris

2008 enabling in Transient elastography

26.05.2011 enabling in Basic ultrasound

14.11.2011 Postgraduate in Internal Medicine, 70/70 cum laude. Università del Piemonte Orientale "A. Avogadro".

UNIVERSITY CAREER

01/12/2012--	Research fellow in Internal Medicine, Dpt. Traslational Medicine Università del Piemonte Orientale- Italy (MED09)

UNIVERSITY POSITIONS

2015-	Member of the Senate, Università del Piemonte Orientale
2011-2014	Dean, Dipartimento di Studi umanistici, Università del Piemonte Orientale
2008-2001	Vice-dean, Facoltà di Lettere e Filosofia, Università del Piemonte Orientale

SCIENTIFIC POSITIONS

2011--	Member of the European association for the study of the liver (EASL)

MAIN FIELDS OF INTEREST

1. Hepatocellular carcinoma (HCC)
2. Viral hepatitis
3. Hepatic steatosis
4. Metabolic disease

CURRENT ISSUES OF RESEARCH

1. **Analysis of A61G polymorphism of Epidermal Growth Factor (EGF) in relation to periodic surveillance of hepatocellular carcinoma (HCC) in cirrhotic patients.**

   Usually HCC arise on cirrhosis, but its aggressiveness and size could be very different case by case. On this base, we evaluated if it is possible to personalize patients follow-up, according to EGF polymorphism. Our results highlight that GG variant was not related with an increased risk of HCC, differently by previously results. These observations underline that is not useful to diversify the follow-up according to EGF polymorphism, which instead correlate with a younger age at diagnosis.

2. **Analysis of interleukin 28B polymorphism (IL28B) nei pazienti affetti da epatopatia cronica C.**
   The pre-activation of <IFN system i a well-known predictor of the HCV antiviral therapy response; starting to this observation we would to verify if the IFN plasma level could depend on il28B polymorphism or on the grade of liver fibrosis. The obtained results showed increased IFN plasma level in HIV/HCV patients, but no relationship with IL28B polymorphism or liver fibrosis, which is correlate with an older age and a greater alcohol consumption.

3. **Evaluation of RDW (red cell distribution width) as a bio-marker of early mortality in patient with hepatocellular carcinoma (HCC).**

   RDW value is related with the survival in different conditions, such as cardiovascular and neoplastic disease, therefore it could be a biomarker useful to stratify the prognosis in HCC

patients. The obtained results showed that RDW values at the moment of HCC diagnosis, are an indipendent and consistent predictor of survival in these patients, reflecting the putative relationship between systemic inflammation and neoplastic progression in hepatocellular carcinoma.

4. **Evaluation of RDW (red cell distribution width) as a bio-marker of rehabilitation outcome in patient referred to a second level neurological rehabilitation center.**

   RDW value is related with the survival in different cardiovascular and neoplastic disease, but there is no evidence of a relation with the clinical outcome after a stroke. To investigate this link, we evaluate patients referred to a second level neurological rehabilitation center, by clinical data analysis, and functional outcome evaluate by the Barthel's scale. Our results showed a relation between RDW and clinical outcome in neurological patients, especially in those with a stroke.

TOP FIVE PAPERS

HEPATITIS C VIRUS CELL ENTRY: ROLE OF LIPOPROTEINS AND CELLULAR RECEPTORS. Burlone ME, Budkowska A. J Gen Virol. 2009 May;90(Pt 5):1055-70. Impact factor 3,568 (citazioni: 71)

GENETIC POLYMORPHISM AT THE APOLIPOPROTEIN E LOCUS AFFECTS THE OUTCOME OF CHRONIC HEPATITIS B. Toniutto P, Fattovich G, Fabris C, Minisini R, Burlone M, Pravadelli C, Peraro L, Falleti E, Caldera F, Bitetto D, Pirisi M. J Med Virol. 2010 Feb;82(2):224-331. Impact factor 2,895 (citazioni 5)

INTERFERON-STIMULATED GENE PATHWAYS IN THE TREATMENT OF VIRAL HEPATITIS. Michela E Burlone, Rosalba Minisini, Mario Pirisi. Future Virology, April 2012, Vol. 7, No. 4, Pages 361-369Dati bibliografici

IL28B POLYMORPHISM, BLOOD INTERFERON-ALPHA CONCENTRATION, AND DISEASE STAGE OF HCV MONO-INFECTED AND HCV-HIV CO-INFECTED PATIENTS. Burlone ME1, Cerutti A, Minisini R, Smirne C, Boccato E, Ceriani E, Rizzo G, Bargiacchi O, Bocchetta S, Occhino G, Pirisi M. Curr HIV Res. 2013 Jan;11(1):50-5

EVALUATION OF THE RED CELL DISTRIBUTION WIDTH AS A BIOMARKER OF EARLY MORTALITY IN HEPATOCELLULAR CARCINOMA. Carlo Smirne, Glenda Grossi, David J. Pinato, Michela E. Burlone, Francesco A. Mauri, Adam Januszewski, Alberto Oldani, Rosalba Minisini, Rohini Sharma, Mario Pirisi. Dig Liver Dis. 2015 Jun;47(6):488-94. doi: 10.1016/j.dld.2015.03.011. Epub 2015 Mar 19.

AWARDS

10/2004-10/2005 Research grant for "Polymorphonuclear cell adhesion in diabetic chronic glomerular inflammatory damage pathogenesis", financed by Piedmont Region.

04/2005 Awarded with a “Young Investigator Boursary” for 40th Annual Meeting of the European Association for the Study of the Liver. Paris , France.

04/2006 Awarded with a “Young Investigator Bursary” for 41st Annual Meeting of the European Association for the Study of the Liver. Wien, Austria.

July 2007 Awarded with “Bando Vinci” bursary from French-Italian University

04/2009 Awarded with a “Young Investigator Bursary” for 44th Annual Meeting of the European Association for the Study of the Liver. Copenhagen, Denmark